NASDAQ:BIOA

BioAge Labs (BIOA) Stock Price, News & Analysis

BioAge Labs logo
$4.77 -0.33 (-6.47%)
Closing price 04:00 PM Eastern
Extended Trading
$4.83 +0.06 (+1.26%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About BioAge Labs Stock (NASDAQ:BIOA)

Advanced

Key Stats

Today's Range
$4.77
▼
$5.13
50-Day Range
$4.77
▼
$8.65
52-Week Range
$4.77
▼
$25.95
Volume
640,566 shs
Average Volume
716,440 shs
Market Capitalization
$219.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00
Consensus Rating
Moderate Buy

Company Overview

BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment.

The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.

Founded in 2015, BioAge is headquartered in Richmond, California. Co-founder Kristen Fortney, Ph.D., serves as the company’s chief executive officer.

AI Generated. May Contain Errors.

BioAge Labs Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

BIOA MarketRank™: 
2.77845117845 of 5 stars

BioAge Labs scored higher than 56% of companies evaluated by MarketBeat, and ranked 899th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioAge Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    BioAge Labs has a consensus price target of $29.00, representing about 508.0% upside from its current price of $4.77.

  • Amount of Analyst Coverage

    BioAge Labs has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioAge Labs' stock forecast and price target.
  • Earnings Growth

    Earnings for BioAge Labs are expected to grow in the coming year, from ($2.59) to ($2.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioAge Labs is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioAge Labs is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioAge Labs has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.84% of the float of BioAge Labs has been sold short.
  • Short Interest Ratio / Days to Cover

    BioAge Labs has a short interest ratio ("days to cover") of 4.34.
  • Change versus previous month

    Short interest in BioAge Labs has recently increased by 8.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioAge Labs does not currently pay a dividend.

  • Dividend Growth

    BioAge Labs does not have a long track record of dividend growth.

  • News Sentiment

    BioAge Labs has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for BioAge Labs this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    1 people have added BioAge Labs to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioAge Labs insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.55% of the stock of BioAge Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    BioAge Labs has minimal institutional ownership at this time.

  • Read more about BioAge Labs' insider trading history.
Receive BIOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAge Labs and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIOA Stock News Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
BTIG Research Reaffirms Buy Rating for BioAge Labs (NASDAQ:BIOA)
See More Headlines

BIOA Stock Analysis - Frequently Asked Questions

BioAge Labs' stock was trading at $13.23 at the start of the year. Since then, BIOA shares have decreased by 63.9% and is now trading at $4.77.

BioAge Labs, Inc. (NASDAQ:BIOA) posted its earnings results on Thursday, November, 5th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.05. The firm earned $298 thousand during the quarter. BioAge Labs had a negative trailing twelve-month return on equity of 31.42% and a negative net margin of 1,253.60%.

BioAge Labs (BIOA) raised $88 million in an initial public offering (IPO) on Friday, May 10th 2013. The company issued 8,000,000 shares at a price of $10.00-$12.00 per share.

Top institutional shareholders of BioAge Labs include a16z Capital Management L.L.C. (7.03%), State Street Corp (2.93%), Goldman Sachs Group Inc. (0.67%) and Profund Advisors LLC (0.17%). Insiders that own company stock include Kristen Fortney, Dov A Md Goldstein and Paul D Rubin.
View institutional ownership trends
.

Shares of BIOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioAge Labs investors own include Intel (INTC), NVIDIA (NVDA), AbbVie (ABBV), Kinder Morgan (KMI), Sorrento Therapeutics (SRNE), JD.com (JD) and Micron Technology (MU).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Jefferies Global Healthcare Conference
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:BIOA
Previous Symbol
NYSE:BIOA
CIK
1709941
Fax
N/A
Employees
62
Year Founded
2015

Price Target and Rating

High Price Target
$60.00
Low Price Target
$8.00
Potential Upside/Downside
+508.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$80.61 million
Net Margins
-1,253.60%
Pretax Margin
-1,253.60%
Return on Equity
-31.42%
Return on Assets
-29.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.51
Quick Ratio
15.51

Sales & Book Value

Annual Sales
$8.99 million
Price / Sales
24.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.54 per share
Price / Book
0.63

Miscellaneous

Outstanding Shares
45,960,000
Free Float
37,893,000
Market Cap
$219.23 million
Optionable
Optionable
Beta
1.19

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:BIOA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners